JPI InvestFranΓ§ais
JPI AI Analyst AI assistant Β· JPI Invest
Answers based on the tool's data Β· not financial advice Β· full analysis (free)
All stocks β€Ί Health Care β€Ί PEN

Are analysts right about Penumbra, Inc. (PEN)?

Health Care Β· price $321 Β· median target $350 (+9%)
In short β€” Over the past 12 months, 54% of analyst price targets on Penumbra, Inc. turned out profitable, for an average return of +18% (across 153 timestamped calls). The current consensus is "Hold" with a median price target of $350 (+9% vs the current $321, from 3 analysts).

πŸ“ˆ See the interactive version (live chart) β†’

πŸ”— Related pages on Penumbra, Inc. β€” Financials & fundamentals  Β·  If I had invested
Current price
$321
Median target (12 mo)
$350 +9%
Analyst accuracy (1 yr)
54%
Avg return / call (1 yr)
+18%
πŸ’° Performance & Β« if I invested Β» πŸ“Š Interactive analysis

Historical analyst accuracy

For Penumbra, Inc., we replayed every analyst price target of the past 12 months and measured the real outcome: 54% were profitable, average return +18% (153 calls). At 3 months: +5% average return (50% profitable). The higher the %, the more often analysts were right on this stock.

Most reliable analysts on this stock (past track record)

Their past track record on this stock (targets replayed against real prices) β€” not a forecast of what will happen.

Analyst / brokerCalls i% profitable iAvg return i
Truist Securities2344%+11%
Canaccord Genuity2070%+27%
Wells Fargo1644%+18%
BTIG1650%+13%
Citigroup1450%+18%

Valuation

Is Penumbra, Inc. overvalued, and is it a good time to buy Penumbra, Inc. right now? If you're wondering, here's a recap to make up your own mind: Penumbra, Inc.'s valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.

The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β€” but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.

MetricPenumbra, Inc.Sector median (Health Care)
P/E79.529.4
Forward P/E52.317.1
Net margin11%12%

πŸ‘‰ Penumbra, Inc. trades above its sector median (79.5 vs 29.4) β€” the market expects higher growth; watch out for disappointment.

πŸ“– P/E, PEG, margin…: see the glossary

Frequently asked questions

Is Penumbra, Inc. a buy right now?

The analyst consensus on Penumbra, Inc. (PEN) is "Hold" (16 bullish, 0 bearish calls over 12 months). This is not advice: historically, 54% of their targets on this stock turned out profitable over 1 year.

What is Penumbra, Inc.'s price target?

The median 12-month price target is $350 (+9% vs $321), ranging from $320 to $374 (3 analysts).

Are analysts accurate on Penumbra, Inc.?

Over 1 year, 54% of analyst targets on Penumbra, Inc. were profitable, for an average return of +18% (across 153 timestamped calls). This is JPI Invest's accuracy metric.

What is the Penumbra, Inc. stock forecast?

Analysts target a median of $350 within 12 months, i.e. +9% vs the current price. The most bullish targets $374, the most cautious $320.

What is the Penumbra, Inc. stock forecast for 2026 or long term (2030)?

Note: analyst targets are 12-month (median $350, +9%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (54%), and the stock's past trajectory.

Is Penumbra, Inc. overvalued?

Its P/E is 79.5, forward P/E 52.3. A forward P/E lower than the current P/E means earnings are expected to grow.

πŸ“Š See the full interactive analysis of Penumbra, Inc. β†’

What is JPI Invest?

JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β€” on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.

Explore JPI Invest for free β†’ How it works: the method β†’

⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.